Page 2 - Lupin

Stocks to Watch, Nov 8: Lupin, Cochin Shipyard, Astral, Emami, RVNL, NHPC

Stocks to watch, November 8, 2024: Cochin Shipyard reported a Q2FY25 net profit of Rs 193 crore, which is slightly lower than Rs 200 crore in the same period last year

Lupin Q2FY25 results: Net profit jumps 74% to Rs 853 cr on strong demand

Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to Rs 853 crore (about $101 million) for the quarter ended Sept. 30

Q2 results today: M&M, Lupin, NHPC, and RVNL among 166 to post earnings

Q2 results today, November 7: Trent, Abbott India, Aditya Birla Fashion and Retail, and more will release their Q2FY25 performance report

Lupin Q2 Preview: Profits may rise 42% YoY led by steady India, US sales

Brokerages expect Lupin to report a strong quarter on a year-on-year basis, while a quieter one sequentially

Ajit Mishra of Religare Broking suggests buying this stock on October 24

Markets remained volatile and ended slightly lower, taking a breather after Tuesday's decline

Drug firm Lupin names Claus Jepsen as President Global specialty business

Drug firm Lupin on Monday said it has appointed Claus Jepsen as President, Global Specialty business. Jepsen joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for rare diseases. "His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business," Lupin CEO Vinita Gupta said.

Buy & Sell, Oct 10; top stock picks by Ajit Mishra of Religare Broking

Havells witnessed a sharp rally after a breakout from multi-month consolidation phase. However, in line with market corrective phase, the stock retraced towards the neckline of its previous breakout

Lupin share down 3% as USFDA issues 5 observations for Biotech unit in Pune

Lupin share price slipped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued five observations for its Pune-based Biotech facility.

Lupin inks pact with Scope Opthalmics to market eyecare products in Mexico

Drug maker Lupin on Monday said it has inked a distribution pact with Ireland-based Scope Ophthalmics to market a product range, indicated for the treatment of various eye conditions, in Mexico. The company has signed a distribution agreement with Scope for the registration and marketing of Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the Optase range in Mexico. The products are used for eye conditions like dry eyes, blepharitis and meibomian gland dysfunction (MGD). "This expansion of our ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin. Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America, Scope CEO Tom Freyne stated. "Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the

Lupin share falls over 2% as USFDA issues 3 observations for Pithampur unit

Lupin share price fell after the United States Food and Drug Administration (USFDA) issued 3 observations for its Pithampur Unit-1, based in Madhya Pradesh.

UBS fears slowdown in India, US pharma markets; gives 'Sell' on 4 stocks

As per UBS, the Indian pharma market is slowing down due to a sharp increase in unbranded generics

Lupin shares hit 52-week high: Here's what is fueling the pharma stock

Lupin shares have yielded a return of 74.72 per cent year-to-date, while the Sensex, on the other hand, has advanced 13.72 per cent in 2024

Dr Reddy's, Lupin recall products in US due to manufacturing issues: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen

Bajaj Finserv, Lupin, REC: Top picks by Chandan Taparia of MOFSL for today

Lupin stock has breached its previous ATH price of 10 years on the monthly chart with massive buying volumes which suggests very bullish sentiment.

Lupin market capitalisation nears Rs 1-trillion mark; shares rise 2%

Lupin share price today: Lupin set to become the seventh pharmaceutical company to achieve Rs 1-trillion market capitalisation feat

MCX, Lupin, TechM, Trent among 5 F&O stocks to Buy ahead of August expiry

Granules, MCX, Colgate, Trent, Dr.Reddy's, Glenmark Pharma, Voltas, Lupin, Tech Mahindra, Coromandel International and Balrampur Chini among F&O stocks are holding a PCR in excess of 1, shows F&O data

Lupin stock rallies 227% in 15 months; set to hit a new high after 9 years

Lupin hit a multi-year high of Rs 2,119, up 3 per cent in intra-day trade, inching close to its record high level of Rs 2,127 touched on October 6, 2015

Lupin stock soars: Analysts bullish on growth but valuation may cap upside

Brokerages sang in unison about Lupin's growth outlook but stayed divided on the valuation front with many calling the current trading values - a bit expensive

Lupin's shares zoom 6%, hit 52-week high on solid Q1 show; details here

Mumbai-based Lupin reported a whopping 77.2 per cent year-on-year (Y-o-Y) increase in profit after tax (PAT) for Q1FY25, reaching Rs 801 crore

Lupin Q1 result: Profit jumps 77% to Rs 801 cr on strong performance

On a sequential basis, the company exhibited a significant 122.9 per cent increase in PAT, with revenue also increasing by 12.6 per cent